These findings suggest that this gene polymorphism might be in linkage disequilibrium with a DRD2 mutation or a mutation in gene close to DRD2, which could increase the risk of dopaminergic therapy-related hallucinations in later stages of PD [117]. The gene discussed is DRD2; the disease is Parkinson disease.